Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
428 studies found for:    Open Studies | Interventional Studies | melanoma
Show Display Options
Rank Status Study
1 Not yet recruiting LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: LY3022855;   Drug: Vemurafenib;   Drug: Cobimetinib
2 Recruiting A Clinical Trial of Patients With Melanoma
Condition: Melanoma
Interventions: Drug: Digoxin Combination;   Drug: Dabrafenib;   Drug: Trametinib
3 Recruiting Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas
Condition: Melanoma
Intervention: Radiation: Protontherapy
4 Recruiting A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Metformin
5 Recruiting A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Condition: Melanoma
Interventions: Drug: pembrolizumab + epacadostat;   Drug: pembrolizumab + placebo
6 Recruiting Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Condition: Melanoma
Interventions: Drug: MK-3475;   Drug: Peginterferon alfa-2b
7 Recruiting BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: BGB324+pembrolizumab;   Drug: BGB324+dabrafenib and trametinib;   Drug: pembrolizumab;   Drug: dabrafenib and trametinib
8 Recruiting Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
Condition: Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Drug: Metformin
9 Not yet recruiting SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
Conditions: Melanoma;   Metastatic Melanoma
Interventions: Radiation: SAbR;   Drug: Ipilimumab;   Drug: Nivolumab
10 Recruiting A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients
Condition: Melanoma
Intervention: Drug: SHR6390
11 Recruiting A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Condition: Melanoma
Interventions: Biological: Poly-ICLC;   Biological: Peptides
12 Recruiting Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
Condition: Melanoma
Intervention: Drug: regorafenib
13 Recruiting A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients
Condition: Melanoma
Intervention: Biological: NKT cells
14 Recruiting PLX3397 KIT in Acral aNd mucOsal Melanoma
Condition: Malignant Melanoma
Intervention: Drug: PLX3397
15 Recruiting Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Tremelimumab;   Drug: MEDI3617
16 Not yet recruiting Nivolumab Plus Radiotherapy in Advanced Melanoma
Condition: Melanoma
Interventions: Biological: Nivolumab;   Radiation: hypofractionned radiotherapy
17 Not yet recruiting Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: Standard therapy or clinical trial;   Drug: Matched targeted therapy;   Drug: Trametinib and / or supportive care
18 Recruiting Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma
Condition: Malignant Melanoma
Intervention: Procedure: Wide Local Excision
19 Recruiting Radiotherapy & Combi in Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Radiation: Palliative radiotherapy;   Drug: Dabrafenib and trametinib (combination)
20 Recruiting Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.